Effect of pioglitazone on receptor activator of nuclear factor-kappa B expression in osteoclast from RAW264.7 cells

National Medical Journal of China

Volumn 90, Issue 32, 2010, Pages 2282-2285

  Jiang, Min ^a   Lü, Shan ^a   Wu, Lin ^a   Liu, Juan ^a   Cheng, Peng ^a   Ding, Guo Xian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Osteoclasts; Peroxisome proliferator activated receptors; Pioglitazone

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL MATURATION; CONTROLLED STUDY; MACROPHAGE; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; MICE; OSTEOCLASTS; PPAR GAMMA; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 84871436312     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.32.013     Document Type: Article

References (14)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 1990, 347: 645-650.
2. Shah P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf, 2010, 9: 347-354.
3. Meier C, Kraenzlin M E, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med, 2008, 168: 820-825.
4. Gimble J M, Robinson C E, Wu X, et al. Peroxisome proliferator activated receptor gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol, 1996, 50: 1087-1094.
5. Kahn S E, Haffner S M, Heise M A, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006, 355: 2427-2443.
6. Defronzo R A. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 2009, 58: 773-795.
7. Lipscombe L L, Gomes T, Levesque L E, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA, 2007, 298: 2634-2643.
8. Teitelbaum S L. Bone resorption by osteoclasts. Science, 2000, 289: 1504-1508.
9. Leibbrandt A, Penninger J M. RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies. Adv Exp Med Biol, 2009, 649: 100-113.
10. TheillL E, Boyle W J, Penninger J M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Ann Rev Immunol, 2002, 20: 795-823.
11. Jones D H, Kong Y Y, Penninger J M. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis, 2002, 61 Suppl 2: ii32-39.
12. Park J Y, Bae M A, Cheon H G, et al. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways. Biochem Biophys Res Commun, 2009, 378: 645-649.
13. Wan Y, Chong L W, Evans R M. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med, 2007, 13: 1496-503.
14. Mbalaviele G, Abu Amer Y, Meng A, et al. Activation of peroxisome proliferator-activated recep tor-gamma pathway inhibits osteoclast differentiation. Biol Chem, 2000, 275: 14388-14393.